Abstracts Archive - Page 660 of 2607 - ACR Meeting Abstracts

Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Emily Fan¹ and Megan Krause², ¹University of Kansas School of Medicine, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…
Abstract Number: 1812 • ACR Convergence 2022
Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
Lingxiao Chen¹, Yue Zhang² and Kazuki Yoshida³, ¹Kolling Institute, Sydney, Australia, ²University of Utah, Salt Lake City, UT, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout is considered the most common inflammatory arthritis in the US with an estimated prevalence of 3.9% based on the National Health and Nutrition…
Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Michael Pillinger¹, Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹NYU Grossman School of Medicine, New York, NY, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…
Abstract Number: 1818 • ACR Convergence 2022
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Naomi Schlesinger¹, ankoor patel¹, Vinod Rustgi¹, Anthony Yeo² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizontherapeutics, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD), but neither the frequency nor severity of NAFLD in gout is well described. Elastography is…
Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Blanka Stiburkova¹, Kateřina Pavelcová¹, Jana Bohatá¹, Karel Pavelka², Lenka Hasíková¹, Jakub Závada¹, Aleš Kvasnička³, Dana Dobešová³ and David Friedecký³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ³Palacky University Olomouc, Olomouc, Czech Republic
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 1801 • ACR Convergence 2022
High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
Kalliopi Klavdianou¹, Jona Kasfeld², Martin Fruth³, Styliani Tsiami⁴, Juergen Braun⁵, Philipp Sewerin⁶, David Kiefer⁵ and Xenofon Baraliakos⁷, ¹'Asklepieion' General Hospital, Department of Rheumatology, Voula, Athens, Greece, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Blikk, Radiologie, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Calcium pyrophosphate dihydrate crystal deposition disease (CPPD, chondrocalcinosis) is known to affect fibrocartilaginous tissue in the large and smaller peripheral joints. The affection of…
Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Amir Bieber² and Reuven Mader¹, ¹Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, ²Emek Medical Center, Raanana, Israel
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…
Abstract Number: 1824 • ACR Convergence 2022
eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
John Albert¹, Aaron Broadwell², Lissa Padnick-Silver³, Brad Marder⁴ and Brian LaMoreaux³, ¹Rheumatic Disease Center, Glendale, WI, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO
Background/Purpose: Chronic kidney disease (CKD) has been associated with gout1 and CKD worsening has been associated with hyperuricemia.2,3 Pegloticase can lower serum uric acid (sUA)…
Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Rachael Flood¹, Colm Kirby¹, yousef Alammari², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Imam Mohammad Ibn Saud Islamic University, RIYADH, Ar Riyad, Saudi Arabia
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…
Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Ernesto Tovar-Sugrañes, Maria-Carmen Lopez-Gonzalez, Cristina Rodriguez-Alvear, Elisabet Perea-Martinez and Mariano Andrès, Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…
Abstract Number: 1800 • ACR Convergence 2022
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Yue Yin¹, Yun Zhang¹, Hong Di¹, Xinxin Han¹ and Xuejun Zeng², ¹Peking Union Medical College Hospital, Beijing, China, ²Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: Gout is an inflammatory disease caused by the deposition of MSU crystals in joints and other parts. At present, little progress in the research…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].